Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Single vs Double vs Triple Agent Therapy in NSCLC
NCT00148395Phase 3Completed
- Sponsor
- Aktion Bronchialkarzinom
- Start
- Jun 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, vinorelbine, carboplatin, cisplatin, mitomycin c and 1 more in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Aktion Bronchialkarzinom. Primary endpoint: Overall Survival. Started Jun 2002; status: completed.
02
Drugs
gemcitabinevinorelbinecarboplatincisplatinmitomycin c
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00148395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148395.